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Background: Surgery is the cornerstone for clinical management of patients with borderline ovarian tumors (BOT).
As these patients have an excellent overall prognosis, perioperative morbidity is the critical point for decision
making when the treatment strategy is developed and the primary surgical approach is defined.
Methods: Clinical and surgical parameters of patients undergoing surgery for primary BOT at our institutions
between 1993 and 2008 were analyzed with regard to perioperative morbidity depending on the surgical approach
(laparotomy vs. laparoscopy).
Results: A total of 105 patients were analyzed (44 with primary laparoscopy [42%], 61 with primary laparotomy
[58%]). Complete surgical staging was achieved in 33 patients at primary surgical approach (31.4%) frequently
leading to formal indication of re-staging procedures. Tumor rupture was significantly more frequent during
laparoscopy compared to laparotomy (29.5% vs. 13.1%, p = 0.038) but no other intraoperative complications were
seen in laparoscopic surgery in contrast to 7 of 61 laparotomies (0% vs. 11.5%, p = 0.020). Postoperative
complication rates were similar in both groups (19.7% vs. 18.2%, p = 0.848).
Conclusions: Irrespective of the surgical approach, surgical management of BOT has acceptable rates of
perioperative complications and morbidity. Choice of initial surgical approach can therefore be made
independent of complication-concerns. As the recently published large retrospective AGO ROBOT study
observed similar oncologic outcome for both approaches, laparoscopy can be considered for staging of
patients with BOT if this appears feasible. An algorithm for the surgical management of BOT patients has
been developed.
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Borderline ovarian tumors (BOT) are epithelial tumors
constituting for approximately 10-20% of all ovarian
neoplasias [1]. As the term borderline implies they clinic-
ally behave intermediate between benign and malignant
tumors. Histologically this is expressed by cellular prolifer-
ation and nuclear atypia without destructive stromal inva-
sion [2]. BOT have an excellent overall prognosis with a* Correspondence: s.mahner@uke.uni-hamburg.de
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reproduction in any medium, provided the or5-year-survival rate of almost 90% across all stages but fre-
quently recur within the abdomen even after more than
ten years [3,4].
Current guidelines recommend similar surgical man-
agement of BOT patients compared to ovarian cancer
patients except for lymphadenectomy [5]. Fertility spar-
ing surgery can be performed when the uterus and at
least part of one ovary are preserved leading to slightly
elevated but acceptable recurrence rates [1,6]. The ma-
jority of BOT patients are diagnosed in early stage when
the disease is still limited to the ovaries (78.5% in FIGO
stage IA/B) [7]. However, the diagnosis of BOT is usuallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nonspecific clinical and diagnostic features as well as
limited diagnostic accuracy of intraoperative histology.
Therefore many patients require re-staging surgery, even
though the prognostic indication for this procedure
remains controversial [8].
The surgical approach for BOT is still under debate.
As laparoscopy became standard approach for benign
ovarian lesions [9] it has not convincingly proven to
guarantee adequate staging and oncologic safety in BOT
patients [10]. Taking the excellent overall survival and
low recurrence rates into account, the degree of peri-
operative morbidity is an important aspect when counsel-
ling BOT patients. We therefore systematically assessed
BOT patients of our institutions focusing on surgical
parameters and complications to evaluate the optimal sur-
gical approach.
Methods
Patients
All patients with primary diagnosis of BOT who
presented for surgery at the University Medical Center
Hamburg-Eppendorf and the Albertinen-Krankenhaus
Hamburg between 1993 and 2008 were retrospectively
investigated. Of 105 analyzed patients, 95 were part of
the retrospective multicenter outcome survey of
AGO-Ovarian Cancer Study Group (ROBOT; AGO-
OVAR OP.5) which has been recently published [11].
Primary surgery was defined as the procedure in
which the diagnosis of BOT was first established irre-
spective of the surgical extend. Depending on preoperative
clinical features of the initial diagnostic workup with
gynecologic examination including vaginal ultrasound and
the surgeon’s surgical skills and preference, the surgical
approach was determined (e.g. tumor size, aspect in ultra-
sound, presence of ascites, comorbidities, BMI, CA125
level). Additional radiologic examinations were performed
if necessary. Solely definite histology was accepted to
establish the diagnosis of BOT but intraoperative histology
was frequently applied to adjust the surgical extend during
primary surgery.
Complete surgical staging was defined as bilateral
salpingoophorectomy, omentectomy, peritoneal washing
and biopsies as well as appendectomy for mucinous
histology. Fertility sparing staging was discussed with
patients of reproductive age to preserve the uterus
and at least a part of one ovary. A thorough explor-
ation of the abdomen was part of each surgery. Re-staging
surgery of BOT patients was defined to be a secondary
surgery in which parts of the recommended staging
were completed. All patients received prophylaxis for
thromboembolism with low-molecular weight heparin
(Enoxaparin-Natrium 20 mg) from the day of surgery
until at least the day of discharge from hospital.Data was retrieved from patients’ records and the
tumor registry. Written informed consent was obtained
from all patients to access their tissue and review their
medical records when they first attended the hospital
according to our investigational review board and ethics
committee guidelines (reference number #190504). All
pathological studies were performed by specialized
gynecopathologists in the department of pathology of
the University Medical Center Hamburg-Eppendorf.
Pathological reports were retrospectively analyzed for
tumor classification, stage, histological subtype, implants
and other prognostic factors such as microinvasion and
micropapillary structure. The tumor staging classifica-
tion of the Fédération Internationale de Gynécologie et
d’Obstétrique (FIGO) [12] was used to determine the
stage of disease.
Analysis of surgical procedures
To analyze the characteristics of the primary surgical
treatment, surgery reports of BOT patients were system-
atically reviewed for localization of the tumor, performed
procedures, the need for conversion from laparoscopy to
laparotomy, occurrence of tumor cyst rupture, duration
of surgery and the result of surgical resection (complete
vs. incomplete). The same characteristics were analyzed
for all re-staging procedures.
To evaluate perioperative morbidity, intraoperative as
well as postoperative complications were analyzed.
Inhospital stay and the required days of intensive care
were noted. Intraoperative events as transfusion of blood
products, cardiac events, bladder or ureter lesions, bowel
lesions and lesions of other abdominal organs were
retrieved from the surgical reports and anesthesiological
protocols. For the postoperative course, medical charts
were analyzed for the number of transfused blood prod-
ucts as well as for postoperative hemorrhage, infections,
septicemia, temperature >38.5°C after surgery, fever
>6 days after surgery, blood glucose dysregulation, de-
layed wound healing or wound breakdown, symptomatic
lymphatic cysts, cardiac and circulatory events, deep
vein thrombosis, postoperative pneumothorax or pleural
effusion, pulmonary embolism, urinary retention, renal
failure, subileus, ileus and the need for re-laparotomy
due to complications.
Statistical analysis
All statistical analyses were conducted with SPSS soft-
ware version 19.0 (SPSS Inc., Chicago, IL, USA).
Mann–Whitney U test was applied as non-parametric
significance test. In addition, Chi-quadrate (Chi2) test
and Fisher’s exact test were performed to analyze the dif-
ference in patient characteristics, surgical parameters and
complications for each surgical approach. P-values less
than 0.05 were regarded as statistically significant.
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BOT patients and primary surgery
A total of 105 patients were analyzed in this study. For
61 cases (58.1%) the primary surgical approach was
by laparotomy, 44 patients (41.9%) initially underwent
laparoscopy. Detailed patient characteristics are listed
in Table 1. Patients in the laparotomy group were sig-
nificantly older with a median age of 59 years (range
13–85 years) compared to 47 years (range 16–86
years) in the laparoscopy group (p = 0.006). Especially
patients in the reproductive age (< 40 years) were
more likely to receive primary laparoscopy (36.4% vs.
16.4%, p = 0.023).
The vast majority of patients underwent surgery
because of suspicious ovarian masses (93.3%), in
seven cases (6.7%) the diagnosis of BOT was
established unexpectedly during surgery for different
reasons (e.g. Caesarean section, suspected appendi-
citis, endometriosis, ovarian torsion). Most patients
(59 of 105, 56.2%) were treated in an early stage
when the disease was still limited to the ovaries
(FIGO stage IA/B). Thirteen patients were diagnosed
and treated with tumor mass extending the ovaries
(13.3%, FIGO stage ≥ IIA). Mucinous histology was
more frequently seen in laparotomies (49.2% vs.
13.6% in laparoscopies, p < 0.001) as these tumors
were more associated with the presence of ascites
than other histologies. Peritoneal implants could be
detected in ten patients (9.5%), only in one case the
implants showed an invasive growth pattern. Forty-
three of all BOT patients (41.0%) had ascites, of
them ten patients (23.3%) with a volume of >500 ml
but without significant impact on the decision of the
surgical approach.
During initial surgery complete tumor resection was
achieved in 90 of all patients (84.8%) and in 66 cases
intraoperative histology was obtained (62.9%). This rate
was significantly higher in laparotomies (83.6%) with 30
consecutive intraoperative diagnoses of BOT compared
to 34.1% and nine intraoperative diagnoses of BOT
in primary laparoscopies (p < 0.001). Only 33 of all
patients (31.4%) underwent complete staging proce-
dures during primary surgery. Of these, 29 were
performed by laparotomy (47.5% of all laparotomies).
In contrast, 4 of the 44 primary laparoscopic surger-
ies led to a complete surgical staging (9.1%, p <
0.001). These rates equalized after re-staging proce-
dures with complete surgical staging in 50.8% of all
laparotomies and 52.3% of all laparoscopies.
Surgical morbidity
In the group of 44 patients undergoing primary laparos-
copy, the surgical approach had to be converted to
laparotomy in 14 patients (31.8%). In three of these cases(21.4%) the conversion was already planned preopera-
tively in case of intraoperative diagnosis of BOT or ovar-
ian cancer. Eight approaches were converted due to
disseminated tumor growth pattern or tumor size and
three due to adhesions, not manageable by laparoscopy.
A detailed overview of the surgical parameters is given
in Table 2. Median operating time did not significantly
differ (112 min vs. 136 min, p = 0.120) but patients
undergoing laparoscopy had a significantly shorter me-
dian inhospital stay for primary surgery (5 days vs.
9 days, p < 0.001). Cyst rupture of the primary tumor
occurred in 21 cases (20.0%) which was significantly
less frequent during laparotomy (13.1%) compared to
laparoscopy (29.5%, respectively, p = 0.038). Sixteen of
all patients (15.2%) were monitored on intermediate
or intensive care units postoperatively. For the major-
ity of patients (91.4%) no blood products had to be
transfused perioperatively, although median postoper-
ative haemoglobin levels were significantly lower com-
pared to preoperative levels (11.2 vs. 13.3 mg/dL, p <
0.001), favouring laparoscopy over laparotomy (11.9
vs.10.9 mg/dL, p = 0.006).
There was a trend for higher perioperative complica-
tion rates in laparotomies compared to laparoscopies
(29.5% vs. 18.2%, p = 0.185) although this finding did not
reach statistical significance. A detailed list of these
events is shown in Table 3 and Figure 1 revealing that
this difference is result of the intraoperative complica-
tion rates. During primary laparoscopy no complica-
tion occurred intraoperatively, while eight patients
experienced postoperative complications (18.2%). In
contrast, intraoperative complications occurred in 7
of 61 laparotomies (11.5% vs. 0%, p = 0.020) and post-
operative complications were noted in 20 patients
(19.7% vs. 18.2%, p = 0.848). An intermittent cardiac
arrest and a bladder lesion occurred during primary
laparotomy in one patient, in another surgery the
spleen had to be removed due to intraoperative le-
sion. Five patients received blood transfusions intra-
operatively. Transfusion of red blood cells was also
the most frequent postoperative event after laparot-
omy with five patients in this group. More serious
postoperative complications included deep vein throm-
bosis after laparotomy as well as acute renal failure and
ileus after laparoscopy. The rate for wound infection and
delayed fever showed a trend for higher rates in laparosco-
pies compared to laparotomies (16.7% vs. 5.9% and
16.7% vs. 11.8%) but without reaching statistical sig-
nificance. Of note, three of these four laparoscopic
cases were observed in laparoscopies intraoperatively
converted to laparotomy.
Re-laparotomy had to be performed in two patients of
the laparoscopy group. In one patient, extensive wound
infection following laparoscopy with conversion to
Table 1 Patient characteristics
Primary approach via laparotomy Primary laparoscopic approach P
(n = 61) (58.1%) (n = 44) (41.9%)
Age, median (years) 59 47 0.006a
range 13-85 16-86
≤40 10 16.4% 16 36.4% 0.023c
41-55 18 29.5% 16 36.4% 0.528c
56-65 12 19.7% 5 11.4% 0.294c
>65 21 34.4% 7 15.9% 0.044c
FIGO stage
I A/B 40 65.6% 19 43.2% 0.029c
I C 13 21.3% 19 43.2% 0.019c
II A-C 1 1.6% 2 4.5% 0.570c
III A/B 3 4.9% 3 6.8% 0.693c
III C 4 6.6% 1 2.3% 0.396c
IV 0 0.0% 0 0.0%
Histologic subtype
serous 27 44.3% 32 72.7% 0.005c
seromucinous 2 3.3% 5 11.4% 0.127c
mucinous 30 49.2% 6 13.6% < 0.001c
endometrioid 2 3.3% 1 2.3% 1.000c
Implants
yes 8 13.1% 2 4.5% 0.140b
- invasive 1 0
- non-invasive 7 2
no 53 86.9% 42 95.5%
Ascites
none 27 44.3% 18 40.9% 0.468b
< 500 ml 22 36.1% 11 25.0%
> 500 ml 8 13.1% 2 4.5%
unknown 4 6.6% 13 29.5%
CA 125 44.6 48.5 0.804a
range 2-2770 6-360
elevated 27 44.3% 16 36.4% 0.594b
within normal limits 24 39.3% 11 25.0%
unknown 10 16.4% 17 38.6%
BMI, median 23,4 24.1 0.904a
range 17,7-43,0 18.6-35.3 17,7-43,0
< 19 3 4.9% 1 2.3% 0.677b
19-24 23 37.7% 15 34.1%
24-30 19 31.1% 11 25.0%
>30 8 13.1% 2 4.5%
unknown 8 13.1% 15 34.1%
ASA, median 2 2 0.010a
range 1-3 1-3 1-3
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Table 1 Patient characteristics (Continued)
1 7 11.5% 13 29.5% 0.020b
2 31 50.8% 14 31.8%
3 9 14.8% 3 6.8%
unknown 14 23.0% 14 31.8%
Overview of the characteristics of all BOT patients (n = 105). Sixty-one patients undergoing primary laparotomy were opposed to 44 patients receiving
primary laparoscopy.
(a: Mann–Whitney U test, b: Chi2 test, c: Fisher’s exact test).
Table 2 Surgical parameters
Primary approach via laparotomy Primary laparoscopic approach P
(n = 61) (58.1%) (n = 44) (41.9%)
Indication for surgery
cystic ovarian lesion 56 91.8% 42 95.5%
- unsuspicious ovarian cyst 0 13
- cystic lesion of unknown dignity 48 29
- suspected ovarian cancer/ BOT 8 0
unexpected diagnosis during surgery for
different reason
5 8.2% 2 4.5%
Conversion of laparoscopy to laparotomy
(reason for conversion)
14 31.8%
intraoperative conditions 11 78.6%
- tumor growth pattern and tumor size 8
- adhesions 3
result of intraoperative histology 3 21.4%
Surgical procedures in primary and re-staging surgery
fertility sparing surgery 9 14.8% 15 34.1%
non-fertility sparing surgery 52 85.2% 29 65.9%
omentectomy 33 54.1% 30 68.2%
appendectomy 35 57.4% 12 27.3%
peritoneal biopsies 37 60.7% 23 52.3%
cytology 49 80.3% 38 86.4%
sampling of lymph nodes or lymphonodectomy 24 39.3% 14 31.8%
- pelvic 19 13
- paraaortic 5 3
Surgical cytoreduction 0.333b
complete 54 88.5% 36 81.8%
incomplete 7 11.5% 8 18.2%
Surgical staging < 0.001b
- complete in primary surgery 30 49.2% 4 9.1%
- incomplete in primary surgery 31 50.8% 40 90.9%
- complete after re-staging surgery 31 50.8 23 52.3
- incomplete after re-staging 30 49.2 21 47.7
Intraoperative histology < 0.001b
obtained 51 83.6% 15 34.1%
- intraoperative diagnosis of BOT 30 9
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Table 2 Surgical parameters (Continued)
not obtained 10 16.4% 29 65.9%
Cyst rupture 0.038b
yes 8 13.1% 13 29.5%
no 53 86.9% 31 70.5%
Duration of surgery, median (min) 136 112 0.120a
range 50-405 47-350
Eks, median 0 0 0.088a
range 0-6 0-2
FFPs, median 0 0 0.342a
range 0-20 0-10
Hb preop, median (mg/dl) 13.4 13.6 0.662a
range 5.6-15.1 10.3-14.8
Hb postop, median (mg/dl) 10.9 11.9 0.006a
range 7.4-13.6 9.5-14.3
Days on ICU, median (days) 0 0 0.014a
range 0-4 0-2
Primary inhospital stay, median (days) 9 5 < 0.001a
range 5-19 0-19
Detailed overview of the surgical procedures as well as the characteristics of surgery and the inhospital stay. Parameters were separately analyzed for laparotomy
(n = 61) and laparoscopy (n = 44).
(a: Mann–Whitney U test, b: Chi2 test).
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experienced a postoperative mechanical ileus due to
adhesions after laparoscopic surgery. Except for one
patient, all patients with perioperative complications had
less than three events during their inhospital stay. For
the other patient undergoing primary laparoscopy
converted to laparotomy, the postoperative course was
complicated by five events in total. Besides postoperative
transfusions and an acute renal failure, the patient
underwent re-laparotomy due to the extensive wound
infection in which a pleural effusion was intraoperatively
drained.
Discussion
The importance of complete surgical staging and the
optimal surgical approach to achieve this aim have to be
discussed with borderline ovarian tumor (BOT) patients
during initial consultation and while the treatment stra-
tegy is being developed.
In this report, we analyzed 105 BOT patients surgically
treated at the University Medical Center Hamburg-
Eppendorf and the Albertinen-Krankenhaus Hamburg
to determine perioperative morbidity depending on
the surgical approach. Forty-four patients initially re-
ceiving laparoscopic surgery were opposed to 61 pa-
tients with primary approach by laparotomy. Of note,
patients in this study were retrospectively included
and not randomly assigned to the surgical approachwhich warrants cautious interpretation due to possible
selection bias. However, owing to the bi-centric
nature of our study, all patients were treated with
comparable surgical standards, received a thorough
perioperative workup and detailed documentation.
Surgeries were performed by a specialized and experi-
enced team of gynecologic oncologists.
In contrast to benign lesions, where it is widely ac-
cepted to perform laparoscopy for adnectomy or cyst-
ectomy [9] no clear selection criteria exist for BOT
patients to define the primary surgical approach [10].
Patients with ovarian cancer require laparotomy to
guarantee best conditions for a thorough exploration,
tumor resection and staging procedures [13]. In BOT
patients, laparoscopy appears to be an alternative as
these tumors are usually diagnosed in early stage
when the disease is limited to the ovaries and lymph-
adenectomy is not included in current recommenda-
tions for surgical staging [5,7,14]. A major concern
regarding laparoscopy are higher rates of cyst rupture
consecutively leading to an iatrogenic spread of tumor
cells with possible impact on the prognosis and clin-
ical course of the patients [10]. This is also reflected
in our study where a significant difference in rates for
cyst rupture was seen, resulting in a significantly
higher rate of FIGO stage IC patients in the laparos-
copy group. Consequences for prognosis were not
evaluated in our analysis. However, previous studies
Table 3 Perioperative complications
Primary approach via laparotomy Primary laparoscopic approach P All surgeries
61 44 105
Overall complications
No complications 43 70.5% 36 81.8% 0.185b 79 75.2%
Yes 18 29.5% 8 18.2% 26 24.8%
Intraoperative complications
No complications 54 88.5% 44 100.0% 0.020b 98 93.3%
Yes 7 11.5% 0 0.0% 7 6.7%
Intraoperative transfusions 5 62.5% 0 5 62.5%
Cardiac arrest 1 12.5% 0 1 12.5%
Bladder lesions 1 12.5% 0 1 12.5%
Ureter lesions 0 0% 0 0 0%
Bowel lesions 0 0% 0 0 0%
Intraoperative splenic injury 1 12.5% 0 1 12.5%
Complications in total 8 100.0% 0 8 100.0%
Postoperative complications/morbidity
No complications 49 80.3% 36 81.8% 0.848b 85 81.0%
Yes 12 19.7% 8 18.2% 20 19.0%
Postoperative transfusion 5 29.4% 1 8.3% 6 20.7%
Postoperative hemorrhage 0 0% 0 0% 0 0%
Blood glucose dysregulation 1 5.9% 0 0% 1 3.4%
Fever >6 days after surgery 1 5.9% 2 16.7% 3 10.3%
Wound infection 2 11.8% 2 16.7% 4 13.8%
Delayed wound healing 1 5.9% 1 8.3% 2 6.9%
Persistent lymphatic cysts 1 5.9% 0 0% 1 3.4%
Circulatory dysregulation 1 5.9% 2 16.7% 3 10.3%
Deep vein thrombosis 2 11.8% 0 0% 2 6.9%
Pulmonary embolism 0 0% 0 0% 0 0%
Acute renal failure 0 0% 1 8.3% 1 3.4%
Urinary retention 1 5.9% 0 0% 1 3.4%
Ileus 0 0% 1 8.3% 1 3.4%
Pleural effusion 0 0% 1 8.3% 1 3.4%
Pain syndrome 1 5.9% 0 0% 1 3.4%
Re-Laparotomy 0 0% 2 16.7% 2 6.9%
Complications in total 16 100.0% 13 100.0% 29 100.0%
Complications of primary laparotomy (n = 61) and laparoscopy (n = 44), multiple complications per patient possible. Besides overall complication rates,
intraoperative and postoperative events are listed separately.
(b: Chi2 test).
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rence rates for these patients when the two surgical
approaches were compared which was recently con-
firmed by the so far largest, retrospective multicenter
outcome survey of AGO-Ovarian Cancer Study Group
(ROBOT; AGO-OVAR OP.5 [10,11]). Potential prog-
nostic consequence must, nevertheless, be considered
when advantages of laparoscopic surgeries as shorterinhospital stay, smaller wound surface and earlier
postoperative mobilisation are discussed with the
patients.
At present, the decision on the surgical approach for
BOT patients is based on preoperative diagnostic fea-
tures, epidemiological aspects and the surgeon’s prefer-
ence. In our cohort, patients receiving laparoscopy were
significantly younger and had a significantly better ASA
Figure 1 Perioperative complications. A. Number of
intraoperative complications. B. Number of postoperative
complications. The number of perioperative complications (1–5) of
patients undergoing surgery for BOT is visualized for primary
laparotomy or laparoscopy, respectively. The percentage of patients
without complications is mentioned in each diagram.
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indication for laparoscopy in the majority of our
patients. Only one third of these patients received
intraoperative frozen section analysis underlining that
the intention of most laparoscopies was more diagnostic
than achieving a definite surgical therapy. As a conse-
quence, the rate of complete tumor resection was lower
and re-staging surgery was formally indicated in the ma-
jority of cases. Fourteen of all 44 laparoscopies (31.8%)
had to be converted to laparotomy which correlates with
other studies reporting of approximately 30% conversion
rates for BOT patients [10]. The majority of conversions
were result of adhesions, disseminated tumor growth
pattern or tumor size.
Intraoperative complications were generally low in our
cohort with an overall rate of 6.7%. No intraoperative
event was registered in primary laparoscopies while in
seven laparotomies complications occurred (11.5%).
Only one patient required mass transfusions with six
packed red blood cells and 20 fresh frozen plasmas
during a complicated laparotomy for an advanced stage
mucinous BOT. To put these rates in context, it is
important to note that the intention and the surgical
extend varied substantially. The rate of complete surgical
staging was significantly higher in the laparotomy group
so that these patients underwent more advanced surgical
steps as hysterectomy and tumor debulking with con-
secutively rising risk for complications. Therefore, the
significant difference in complications has to be regardedcautiously and should not lead to consequences in man-
agement alone.
Interestingly, postoperative morbidity and complica-
tions in the present study were comparable irrespect-
ive of the surgical approach (19.7% for laparotomy vs.
18.2% for laparoscopy). For all patients, postoperative
hemoglobin levels were significantly lower compared
to preoperative levels, but blood transfusions were
only needed in six patients during the postoperative
course. This was significantly more frequent following
laparotomy while the rate of wound infections and
delayed fever tended to be higher in the laparoscopy
group. However, this was not statistically significant
and three of four cases with postoperative infections
occurred after laparoscopies converted to laparoto-
mies. Most serious events in the overall cohort were
two deep vein thromboses, one patient with acute
renal failure and ileus requiring surgical revision.
To the best of our knowledge, there are no reports
available focusing on complication rates of BOT patients
so that a direct comparison of our cohort and published
series is not possible. For primary ovarian cancer, peri-
operative complication rates from 8 to 58% have been
described [15-17]. In a previous study of our group
concentrating on advanced stage ovarian cancer, we
observed 36.0% perioperative complications rates after
radical surgical treatment [17]. In contrast to our BOT
patients, all of these surgeries were performed by lapar-
otomy, the majority of the patients had advanced stage
disease (94.3% FIGO stage IIIC/IV ovarian cancer) re-
quiring radical procedures as bowel resection in 62.1%
of cases or systematic pelvic and paraaortic lymphade-
nectomy in 73.0%. This underlines that the principal sur-
gical extend for BOT patients compared to ovarian
cancer patients is different.
We therefore regard this first report specifically con-
centrating on surgical parameters and perioperative
morbidity of BOT patients as an important basis for fur-
ther, preferably multicentric analyses. From our perspec-
tive a one-timed approach should be aimed applying
intraoperative fresh frozen section analysis to adjust the
surgical extend. However, the accuracy of intraoperative
diagnosis for BOT is rather low and postponing the
definite surgical management to a completion surgery
appears to be an inevitable alternative [14,18]. After
diagnosis of BOT intraoperatively or in definite histology
complete surgical staging has to be performed. Based on
the initial gynecological examination the surgical
approach has to be defined by the surgeon. In case of
unsuspicious ovarian lesions laparoscopy is preferred, for
cystic tumors of unknown dignity or suspected BOT
laparoscopy can be considered if tumor appears manage-
able by laparoscopy and there is no evidence for abdom-
inal tumor dissemination. We developed a treatment
Figure 2 Algorithm for surgical management of BOT patients.
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the decision making process (see algorithm Figure 2).
The present results might therefore help gynecologic on-
cologists to put surgical management and perioperative
morbidity into perspective.Conclusions
In the present study of 105 BOT patients, we could
demonstrate that surgical treatment has acceptable com-
plication rates and perioperative morbidity irrespective
of the surgical approach.
As patients in this study were not randomly assigned
to primary laparoscopic or open surgical approach, dif-
ferences regarding the primary indication for surgery
and intraoperative procedures may influence the results.
Future prospective trials are therefore highly desirable to
allow evidence based recommendations for the surgical
approach and a concise appraisal of surgical morbidity
of BOT patients.
Until then, choice of initial surgical approach can pri-
marily be made independent of complication-concerns.
As the recently published large retrospective AGO
ROBOT study observed similar oncologic outcome for
both approaches, laparoscopy is preferred for unsuspicous
ovarian lesions and can be considered for surgical staging
in case of localized tumor and feasible intraoperative
conditions.Competing interests
All authors declare that they do not have any financial or personal
relationship with other people or organizations that could inappropriately
influence this work.
Authors’ contributions
FT and SM were responsible for the concept and design of the presented
study, analyzed the data and prepared the manuscript. JDR, UH and FT
collected main parts of the data, participated in the study design and
supported the statistical analysis. MC performed the histopathological
analyses leading to the diagnosis of BOT. All authors were involved in the
data acquisition and quality control for the trial. All authors supported the
manuscript editing, read and approved the final manuscript.
Funding
No external funding sources were involved during this analysis.
Author details
1Department of Gynecology and Gynecologic Oncology, University Medical
Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
2Department Gynecology and Obstetrics, Albertinen-Krankenhaus, Hamburg,
Germany. 3Institute of Pathology, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany.
Received: 11 May 2013 Accepted: 29 June 2013
Published: 9 July 2013
References
1. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A: Conservative surgery for
borderline ovarian tumors: a review. Gynecol Oncol 2006, 100:185–191.
2. Acs G: Serous and mucinous borderline (low malignant potential) tumors
of the ovary. Am J Clin Pathol 2005, 123(Suppl):S13–S57.
3. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT,
Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 6th annual
report on the results of treatment in gynecological cancer. Int J Gynaecol
Obstet 2006, 95(Suppl 1):S161–192.
Trillsch et al. Journal of Ovarian Research 2013, 6:48 Page 10 of 10
http://www.ovarianresearch.com/content/6/1/484. Du Bois A, Ewald-Riegler N, du Bois O, Harter P: Borderline tumors of the
ovary - a systematic review, German. Geburtsh Frauenheilk 2009, 69:807–833.
5. Trillsch F, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jaenicke F, du Bois
A: Clinical management of borderline ovarian tumors. Expert Rev
Anticancer Ther 2010, 10:1115–1124.
6. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T: Management of
borderline ovarian tumors: results of an Italian multicenter study. Gynecol
Oncol 2006, 101:255–260.
7. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S:
Survival among women with borderline ovarian tumors and ovarian
carcinoma: a population-based analysis. Cancer 2004, 100:1045–1052.
8. Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E:
Restaging surgery for women with borderline ovarian tumors: results of
a French multicenter study. Cancer 2004, 100:1145–1151.
9. Deffieux X, Morice P, Camatte S, Fourchotte V, Duvillard P, Castaigne D:
Results after laparoscopic management of serous borderline tumor of
the ovary with peritoneal implants. Gynecol Oncol 2005, 97:84–89.
10. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E: Laparoscopic
management of borderline ovarian tumors: results of a French
multicenter study. Ann Oncol 2005, 16:403–410.
11. du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou
C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, et al: Borderline tumours
of the ovary: a cohort study of the arbeitsgmeinschaft gynakologische
onkologie (AGO) study group. Eur J Cancer 2013, 49:1905–1914.
12. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and
gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009, 105:3–4.
13. Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Pfisterer J, du Bois A:
Prognostic factors for complete debulking in first- and second-line
ovarian cancer. Int J Gynecol Cancer 2009, 19(Suppl 2):S14–S17.
14. Tempfer CB, Polterauer S, Bentz EK, Reinthaller A, Hefler LA: Accuracy of
intraoperative frozen section analysis in borderline tumors of the ovary:
a retrospective analysis of 96 cases and review of the literature.
Gynecol Oncol 2007, 107:248–252.
15. Guidozzi F, Ball JH: Extensive primary cytoreductive surgery for advanced
epithelial ovarian cancer. Gynecol Oncol 1994, 53:326–330.
16. Shimada M, Kigawa J, Minagawa Y, Irie T, Takahashi M, Terakawa N:
Significance of cytoreductive surgery including bowel resection for
patients with advanced ovarian cancer. Am J Clin Oncol 1999, 22:481–484.
17. Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, Mahner S:
Perioperative morbidity and outcome of secondary cytoreduction for
recurrent epithelial ovarian cancer. Eur J Surg Oncol 2010, 36:583–588.
18. Gultekin E, Gultekin OE, Cingillioglu B, Sayhan S, Sanci M, Yildirim Y: The
value of frozen section evaluation in the management of borderline
ovarian tumors. J cancer res therap 2011, 7:416–420.
doi:10.1186/1757-2215-6-48
Cite this article as: Trillsch et al.: Surgical management and
perioperative morbidity of patients with primary borderline ovarian
tumor (BOT). Journal of Ovarian Research 2013 6:48.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
